Research guides

BPC-157 and TB-500 blend: what the research says

Two repair peptides in one vial and no published study of the pair. What each component's literature covers, and why a blend is weaker evidence than its parts.

Available in the catalogue

Supplied as research material. Sizes and pricing are on the product page. Availability is not a statement about what a compound does.

This is the most widely sold blend in the catalogue and the one with the largest gap between how confidently it is described elsewhere and what has actually been published about it. The short version: the two peptides have been studied, the combination has not.

What is in the vial

BPC-157, a synthetic fifteen-residue peptide from a protein found in human gastric juice, and TB-500, a fragment associated with thymosin β4. Each has its own article and its own reference page.

Why the two get paired

The stated rationale is that they reach overlapping outcomes by non-overlapping routes: BPC-157's animal literature centres on angiogenesis and growth factor receptor expression, TB-500's on actin binding and cell migration. Two mechanisms, one target tissue.

That is a coherent hypothesis. It is worth being clear that a coherent hypothesis is what it is — nobody has run the experiment.

Three reasons a blend is weaker evidence than its parts

  • Nobody studied the combination. Two literatures about two molecules do not add up to a literature about a mixture, because interaction is exactly the thing neither literature measured.
  • Nobody published a basis for the ratio. A blend fixes the proportion of its components, and that proportion is a formulation decision. No published work establishes what ratio, if any, was studied or why.
  • An observation cannot be attributed. Anything seen in an experiment using a multi-component vial belongs to the vial, not to a component — which makes a blend a poor research tool for the same reason a non-selective compound is.

The component caveat that carries over

BPC-157's in-vivo literature originates overwhelmingly from a single research group, and TB-500 as sold is a fragment rather than the thymosin β4 molecule most of that literature studied. Both caveats survive into the blend, and combining two compounds whose individual evidence carries an asterisk does not cancel the asterisks out.

What studies reported

Each entry states what a study examined and the model it used. Nothing below describes an outcome for a person.

Everything below is drawn from published research, and each entry names the model the study used. Approval status varies by compound and by country, and nothing described here is supplied as a medicine or for use in a person.

Adverse and null findings reported

No dedicated safety study has been published for this compound. That is not a finding that none exists — it means the question has not been asked in print, and the gaps below say so.

What the research does not establish

An absence cannot be cited, so these are stated plainly. They are the part of the picture that silence would otherwise hide.

  • No published study investigates this combination. Everything known about the contents of this vial comes from work on the individual components, tested separately.
  • No published work establishes a basis for the ratio in which the two are combined, which is a formulation decision rather than a studied variable.
  • Because the vial holds two active molecules, any observation made with it cannot be attributed to either one. That limits its usefulness as a research tool independently of anything about the components.
  • The caveats attached to each component carry over undiminished: BPC-157's animal literature comes largely from one research group, and the fragment sold as TB-500 is not the thymosin β4 molecule most of that work studied.
  • Neither component has a completed published randomised controlled trial in humans, so the blend inherits two incomplete evidence bases rather than one.
  • No safety study of the combination has been published, and safety data on two compounds tested separately is not safety data on a mixture.

Common questions

Is the BPC-157 / TB-500 blend more effective than either alone?
No published study compares them. The combination has not been investigated, so any claim that the pair outperforms either component is an assumption rather than a finding.
Why are these two peptides sold together?
The stated rationale is that they act on similar tissue repair outcomes through different mechanisms — angiogenesis and growth factor signalling for one, actin binding and cell migration for the other. It is a coherent hypothesis that nobody has tested.
Does the research on each peptide apply to the blend?
Only to the components, not to the mixture. Interaction between two molecules is precisely what studies of each one separately cannot measure.
Is a blend a good research tool?
Generally not. An observation made with a two-component vial cannot be attributed to either component, which is the same attribution problem that makes non-selective compounds poor tools.
Is this blend approved as a medicine?
No, in any jurisdiction, and neither is either component. It is supplied here as a laboratory reagent for in-vitro research and not for human or veterinary use.

Compounds covered

The reference page for each compound this article discusses.

Related articles

All guides